Viridian Therapeutics (LTS:0K1R) Beginning Cash Position : $99.59 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Viridian Therapeutics Beginning Cash Position?

Viridian Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2025 was $99.59 Mil.

Viridian Therapeutics's quarterly Beginning Cash Position increased from Sep. 2024 ($107.67 Mil) to Dec. 2024 ($200.32 Mil) but then declined from Dec. 2024 ($200.32 Mil) to Mar. 2025 ($99.59 Mil).

Viridian Therapeutics's annual Beginning Cash Position increased from Dec. 2022 ($42.30 Mil) to Dec. 2023 ($155.58 Mil) but then declined from Dec. 2023 ($155.58 Mil) to Dec. 2024 ($102.83 Mil).

Viridian Therapeutics Beginning Cash Position Historical Data

The historical data trend for Viridian Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viridian Therapeutics Beginning Cash Position Chart

Viridian Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beginning Cash Position

Get a 7-Day Free Trial

24.85

45.90

42.30

155.58

102.83

Viridian Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Beginning Cash Position	Get a 7-Day Free Trial															102.83	91.64	107.67	200.32	99.59

Viridian Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Viridian Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Viridian Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Viridian Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viridian Therapeutics Inc (LTS:0K1R) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

VRDN:USA 1S1:Germany

Address

221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453

Website

https://www.viridiantherapeutics.com

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics Headlines

No Headlines